Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Personalized Ubiquitination Signatures for Predicting Response to Proteasome Inhibitor-Based Therapy of MM Patients

Haim Tsubery, PhD, Lerman Gali, PhD, Kronenfeld Gali, MSc, Itamar Sela, PhD, Yifat Merbl, PhD, Ayelet Itzhaki-Alfia, PhD, Svetlana Trestman, MD, Yael C Cohen, MD, Irit Avivi, MD

Blood (2019) 134 (Supplement_1): 3371.

https://doi.org/10.1182/blood-2019-125274

Published: 2019

Journal Articles

Combination Therapy Targeting CKS1-Dependent Protein Degradation Reduces AML Burden Whilst Protecting Normal Haematopoietic Stem Cellsfrom Cytarabine Toxicity

William Grey, PhD MSc, Pedro Casado-Izquierdo, Pedro Cutillas, PhD, Dominique Bonnet, PhD

Blood (2019) 134 (Supplement_1): 2535.

https://doi.org/10.1182/blood-2019-121667

Published: 2019

Journal Articles

Leukemogenic Functions of Mutant ASXL1 Are Regulated By CDK-Mediated Phosphorylation

Shuhei Asada, MD PhD, Susumu Goyama, MD PhD, Reina Takeda, MD, Keita Yamamoto, MD, Hiroko Kozuka-Hata, PhD, Masaaki Oyama, PhD, Daichi Inoue, MD PhD, Hiroaki Honda, MD PhD, Toshio Kitamura, MD PhD

Blood (2019) 134 (Supplement_1): 731.

https://doi.org/10.1182/blood-2019-125959

Published: 2019

Journal Articles

Lysosomal Activation Is Required for Priming of Quiescent Hematopoietic Stem Cells

Tasleem Arif, PhD, Raymond Liang, PhD, Maio Lin, Msc, Svetlana Kalmikova, Msc, Artem Kasianov, PhD, Dmitri Papatsenko, PhD, Saghi Ghaffari, PhD MD

Blood (2019) 134 (Supplement_1): 722.

https://doi.org/10.1182/blood-2019-131934

Published: 2019

Journal Articles

FBXO11 Activates Erythroid Gene Transcription By Degrading Heterochromatin-Associated Protein BAHD1

Peng Xu, PhD, Daniel C. Scott, PhD, Xing Tang, PhD, Yu Yao, MD, Yong-Dong Wang, PhD, Wenjian Bi, PhD, Lance E. Palmer, PhD, Ruopeng Feng, PhD, Arno F. Alpi, PhD, Chunliang Li, PhD, Yong Cheng, PhD, Brenda A. Schulman, PhD, Mitchell J. Weiss, MD PhD

Blood (2018) 132 (Supplement 1): 529.

https://doi.org/10.1182/blood-2018-99-117362

Published: 2018

Journal Articles

Ets1 Enhances Context-Dependent Notch1 Activity in T-Cell Leukemia

Anna McCarter, BS, Ran Yan, Amparo Serna Alarcon, Catherine Chang, Erin Kim, Cher Sha, Yiran Liu, Qing Wang, PhD, Luke F. Peterson, PhD, Rork Kuick, Russell Ryan, MD, Moshe Talpaz, MD, Linda Samuelson, PhD, Michael Ostrowski, PhD, Mark Y Chiang, MD PhD

Blood (2018) 132 (Supplement 1): 2595.

https://doi.org/10.1182/blood-2018-99-111376

Published: 2018

Journal Articles

Mll -Partial Tandem Duplication ( Mll -PTD) Causes Pseudohypoxia and Hypermethylation of the Epigenome through Suppression of Mitochondrial Complex II

Asumi Yokota, PhD, Lulu Zhang, PhD, Xiaomei Yan, MD PhD, Xiaomin Feng, MD PhD, Lijun Wen, MS, George Freudiger, Maria Rife, Ally Woeste, Yoshihiro Hayashi, MD PhD, Gang Huang, PhD

Blood (2018) 132 (Supplement 1): 1311.

https://doi.org/10.1182/blood-2018-99-112529

Published: 2018

Journal Articles

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Simon Brille, Iris Fey, BSc., Frank Neumann, MDPhD, Allison Berger, PhD, Ron-Patrick Cadeddu, PhD, Martina Rudelius, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2017) 130 (Supplement 1): 5298.

https://doi.org/10.1182/blood.V130.Suppl_1.5298.5298

Published: 2017

Journal Articles

TET2 and MSH6: A Novel Role for MMR in the Pathogenesis of Myeloid Malignancies

Edward F Greenberg, MD, Cassandra M. Hirsch, BS, Feng Pan, PhD, Babal K Jha, PhD, Yihong Guan, PhD, Valeria Visconte, PhD, Dewen You, PhD, Guangbo Qu, PhD, Amy Graham, Bartlomiej P. Przychodzen, MSc, Thomas Laframboise, PhD, Hideki Makishima, MD PhD, Daniel Gackowski, PhD, Ryszard Ólinski, Professor, Yu-Wei Cheng, PhD, Mikkael A. Sekeres, MD MS, Mingjiang Xu, MDPhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 1668.

https://doi.org/10.1182/blood.V130.Suppl_1.1668.1668

Published: 2017

Journal Articles

SYK Inhibition Disrupts the Cross-Talk Between B-Cell Activation Factor (BAFF) and B-Cell Receptor (BCR) and Thereby Antagonizes Mcl-1 in Chronic Lymphocytic Leukemia (CLL) B-Cells

Cody Paiva, BS, Taylor Rowland, Olga Danilova, Bhargava Sreekantham, Stephen E Spurgeon, MD, Alexey V Danilov, MD PhD

Blood (2016) 128 (22): 303.

https://doi.org/10.1182/blood.V128.22.303.303

Published: 2016

Journal Articles

Targeting Autophagy in Myelodysplastic Syndromes

Valeria Visconte, PhD, Steffan T. Nawrocki, PhD, Bartlomiej P Przychodzen, MSc, Kevin R. Kelly, MD PhD, Mei Yin, Yvonne Parker, Michael J. Clemente, M.S., John Barnard, PhD, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Daniel Lindner, Heesun J Rogers, MD PhD, Jaroslaw P Maciejewski, MD PhD FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4295.

https://doi.org/10.1182/blood.V128.22.4295.4295

Published: 2016

Journal Articles

SYK-Inhibitor Bay 61-3606 Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma Cells Independent of SYK Inhibitory Effects but Via Degradation of IKZF1/3

Shirong Li, PhD, Jing Fu, PhD, Jing Wu, MD PhD, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2016) 128 (22): 4477.

https://doi.org/10.1182/blood.V128.22.4477.4477

Published: 2016

Journal Articles

Proteasome Inhibitor-Adapted Myeloma Cells That Lack Proteasome Gene Mutations Resist Highly Efficient Proteasome Inhibition and Show Proteomic Alterations That Suggest Complex Metabolic Changes

Lenka Besse, PhD, Guillem Soriano, Nan Li, Andrej Besse, Marianne Kraus, Juergen Bader, Tobias Christian Silzle, MD, Nico Meeuwenoord, Hans den Dulk, Herman S Overkleeft, Bogdan Florea, Christoph Driessen, MD

Blood (2015) 126 (23): 1278.

https://doi.org/10.1182/blood.V126.23.1278.1278

Published: 2015

Journal Articles

FBXO10 Targets HGAL for Degradation

Fengjie Guo, PhD, Xiaoyu Jiang, PhD, Domenico Roberti, Lixin Rui, PhD, Izidore S Lossos, MD

Blood (2015) 126 (23): 3904.

https://doi.org/10.1182/blood.V126.23.3904.3904

Published: 2015

Journal Articles

Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs

Rakesh Verma, PhD, Zifeng Mai, MS, Mina Xu, MD, Lin Zhang, Kavita Dhodapkar, MBBS, Madhav V Dhodapkar, MD

Blood (2015) 126 (23): 913.

https://doi.org/10.1182/blood.V126.23.913.913

Published: 2015

Journal Articles

A Novel Non-Canonical Phosphodegron Regulates EZH2 Proteasomal Degradation and H3K27 Trimethylation Activity in Hematopoietic Malignancies

Anagh A Sahasrabuddhe, PhD, Xiaofei Chen, PhD, Thirunavukkarasu Velusamy, PhD, Fuzon Chung, PhD, Megan S Lim, MD PhD, Kojo S.J. Elenitoba-Johnson, MD

Blood (2014) 124 (21): 1678.

https://doi.org/10.1182/blood.V124.21.1678.1678

Published: 2014

Journal Articles

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma

Jennifer E. Amengual, MD, Paul M Johannet, Xavier Jirau-Serrano, BS, Kelly Zullo, BS, Daniela Hoehn, MD, PhD, Govind Bhagat, MD, Maximilian Lombardo, B.S., Luigi Scotto, PhD, Simon S Jones, PhD, Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 648.

https://doi.org/10.1182/blood.V122.21.648.648

Published: 2013

Journal Articles

Dual Role Of MERIT40 In Hematopoietic Stem and Progenitor Cells

Krasimira Rozenova, PhD, Jing Jiang, PhD, Chao Wu, Junmin Wu, Bernadette Aressy, PhD, Roger Greenberg, MD, PhD, Wei Tong, PhD

Blood (2013) 122 (21): 797.

https://doi.org/10.1182/blood.V122.21.797.797

Published: 2013

Journal Articles

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma

Jennifer E Amengual, MD, Paul M Johannet, Simon S Jones, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 1650.

https://doi.org/10.1182/blood.V120.21.1650.1650

Published: 2012

Journal Articles

Protein Synthesis and Degradation in the Late Stages of Megakaryocyte Maturation Trigger Proplatelet Formation

Kellie R Machlus, PhD, Dallas Shi, PhD, Andrew S Weyrich, PhD, Joseph E Italiano, Jr., PhD

Blood (2012) 120 (21): 1218.

https://doi.org/10.1182/blood.V120.21.1218.1218

Published: 2012

NARROW

Personalized Ubiquitination Signatures for Predicting Response to Proteasome Inhibitor-Based Therapy of MM Patients

Combination Therapy Targeting CKS1-Dependent Protein Degradation Reduces AML Burden Whilst Protecting Normal Haematopoietic Stem Cellsfrom Cytarabine Toxicity

Leukemogenic Functions of Mutant ASXL1 Are Regulated By CDK-Mediated Phosphorylation

Lysosomal Activation Is Required for Priming of Quiescent Hematopoietic Stem Cells

FBXO11 Activates Erythroid Gene Transcription By Degrading Heterochromatin-Associated Protein BAHD1

Ets1 Enhances Context-Dependent Notch1 Activity in T-Cell Leukemia

Mll -Partial Tandem Duplication ( Mll -PTD) Causes Pseudohypoxia and Hypermethylation of the Epigenome through Suppression of Mitochondrial Complex II

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

TET2 and MSH6: A Novel Role for MMR in the Pathogenesis of Myeloid Malignancies

SYK Inhibition Disrupts the Cross-Talk Between B-Cell Activation Factor (BAFF) and B-Cell Receptor (BCR) and Thereby Antagonizes Mcl-1 in Chronic Lymphocytic Leukemia (CLL) B-Cells

Targeting Autophagy in Myelodysplastic Syndromes

SYK-Inhibitor Bay 61-3606 Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma Cells Independent of SYK Inhibitory Effects but Via Degradation of IKZF1/3

Proteasome Inhibitor-Adapted Myeloma Cells That Lack Proteasome Gene Mutations Resist Highly Efficient Proteasome Inhibition and Show Proteomic Alterations That Suggest Complex Metabolic Changes

FBXO10 Targets HGAL for Degradation

Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs

A Novel Non-Canonical Phosphodegron Regulates EZH2 Proteasomal Degradation and H3K27 Trimethylation Activity in Hematopoietic Malignancies

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma

Dual Role Of MERIT40 In Hematopoietic Stem and Progenitor Cells

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma

Protein Synthesis and Degradation in the Late Stages of Megakaryocyte Maturation Trigger Proplatelet Formation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only